Humanoid Global Invests CAD $150,000 in MBody AI to Accelerate Robotics Innovation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: Yahoo Finance
- Strategic Investment: Humanoid Global Holdings Corp. has completed a CAD $150,000 investment in MBody AI, aimed at accelerating innovation in the autonomous robotics sector, which is expected to drive market expansion across multiple industries.
- Technological Advantage: MBody AI's hardware-agnostic software platform enables robots to achieve real-time perception and adaptive decision-making, allowing customers to realize up to 90% labor cost savings, thereby enhancing operational efficiency and reducing costs.
- Market Potential: MBody AI has already been deployed within Fortune 500 companies, demonstrating the feasibility of its technology in high-traffic environments, with future prospects for broader deployment across hospitality, healthcare, and logistics sectors.
- Leadership Team: MBody AI's leadership team possesses extensive experience in AI and robotics, with CEO John Fowler having successfully raised over $200 million, showcasing the company's strong capabilities and growth potential within the industry.
Analyst Views on MBAI
About MBAI
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
